T-lymphocytes and cytokines in sarcoidosis
C Agostini, A Meneghin… - Current opinion in …, 2002 - journals.lww.com
In the last few years, a number of reports have clearly shown that pulmonary T lymphocytes
have evolved a number of effector mechanisms to respond to foreign antigens, ranging from …
have evolved a number of effector mechanisms to respond to foreign antigens, ranging from …
[HTML][HTML] Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study
AC Schutt, WM Bullington, MA Judson - Respiratory medicine, 2010 - Elsevier
BACKGROUND: Most issues concerning pharmacotherapy of pulmonary sarcoidosis have
not been resolved in clinical trials. The objective was to survey sarcoidosis experts …
not been resolved in clinical trials. The objective was to survey sarcoidosis experts …
[HTML][HTML] Clinical manifestations, diagnosis, and treatment of sarcoidosis
P Ungprasert, JH Ryu, EL Matteson - Mayo Clinic Proceedings: Innovations …, 2019 - Elsevier
The focus of this review is current knowledge about the epidemiology, clinical
manifestations, diagnosis, and treatment of both pulmonary sarcoidosis and extrapulmonary …
manifestations, diagnosis, and treatment of both pulmonary sarcoidosis and extrapulmonary …
Relapses of sarcoidosis: what are they and can we predict who will get them?
RP Baughman, MA Judson - European Respiratory Journal, 2014 - Eur Respiratory Soc
Granulomatous inflammation in the lung may occur from a variety of causes. Many of these
are the result of specific antigens that reach the lung and induce a granulomatous response …
are the result of specific antigens that reach the lung and induce a granulomatous response …
Sarcoidosis: an update on current pharmacotherapy options and future directions
P Brito-Zerón, R Pérez-Alvarez, L Pallarés… - Expert opinion on …, 2016 - Taylor & Francis
Introduction: Sarcoidosis is a systemic disease of unknown etiology characterized by the
development of non-caseating epitheloid granulomas. The lungs are the most commonly …
development of non-caseating epitheloid granulomas. The lungs are the most commonly …
Comparative evaluation of serum markers in pulmonary sarcoidosis
S Miyoshi, H Hamada, T Kadowaki, N Hamaguchi, R Ito… - Chest, 2010 - Elsevier
Background Although several serum markers have shown their ability to reflect lymphocytic
alveolitis and disease progression in pulmonary sarcoidosis, to our knowledge no prior …
alveolitis and disease progression in pulmonary sarcoidosis, to our knowledge no prior …
Pulmonary sarcoidosis
DR Thrasher, DD Briggs Jr - Clinics in chest medicine, 1982 - Elsevier
A disease of apparently altered immunity, sarcoidosis is manifested in multiple organ
systems of the body, but especially in the lungs, eyes, skin, and reticuloendothelial system …
systems of the body, but especially in the lungs, eyes, skin, and reticuloendothelial system …
Medical therapy of sarcoidosis
RP Baughman, EE Lower - Seminars in respiratory and critical …, 2014 - thieme-connect.com
For treatment of sarcoidosis, one should develop a long-term management plan. Factors to
be considered include the organ involvement and severity of symptoms. Different organ …
be considered include the organ involvement and severity of symptoms. Different organ …
Obstructive sarcoidosis
P Laohaburanakit, A Chan - Clinical reviews in allergy & immunology, 2003 - Springer
Sarcoidosis is a systemic granulomatous disease that frequently involves the lung. Although
classically thought of as a restrictive lung disease, airway obstruction has become a …
classically thought of as a restrictive lung disease, airway obstruction has become a …
Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations
SG West - Current opinion in rheumatology, 2018 - journals.lww.com
Evidence-based treatment guidelines do not exist for most sarcoidosis clinical
manifestations. Therefore, clinical care of these patients must rely on expert opinion …
manifestations. Therefore, clinical care of these patients must rely on expert opinion …